Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience

References

• Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878–87.
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368:1867–77.
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 2014;370:222–32.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370:211–21.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Dusheiko G, Salupere R, Mangia A, Flisiak R, Hyland R, et al. Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial. Hepatology 2013;58:733A–4A.
   Web of Science ®Google Scholar
• Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, et al. All-oral 12-week combination treatment with daclatasvir (DCV) and sofosbuvir (SOF) in patients infected with HCV genotype (GT) 3: ALLY-3 phase 3 study. Hepatology 2014;60:6–7.
   Google Scholar
• Gane EJ, Huyland RH, An D, Svarovskaia ES, Pang PS, Brainard D, Stedman CA. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology 2015. [Epub ahead of print]. doi: 10.1053/j.gastro.2015.07.063.
   Google Scholar
• European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 2015;63:199–236.
   Google Scholar
• Hadziyannis SJ, Sette H, Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346–55.
   PubMed Web of Science ®Google Scholar
• Lagging M, Langeland N, Pedersen C, Farkkila M, Buhl MR, Morch K, et al. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 2008;47:1837–45.
   PubMed Web of Science ®Google Scholar
• Färkkilä M. C-hepatiitin hoito: miten ja milloin? Duodecim 2010;126:41–8.
   PubMedGoogle Scholar
• Lagging M, Alsio A, Langeland N, Pedersen C, Farkkila M, Buhl MR, et al. Early determination of hepatitis C virus RNA may help to decide the duration of therapy for chronic hepatitis C virus genotype 2/3 infection. Hepatology 2011;53:1067–8.
   PubMed Web of Science ®Google Scholar
• Lagging M, Alsio S, Hellstrand K, Norkrans G. Is HCV RNA analysis at day 7 cost-effective in deciding the duration of therapy in chronic HCV genotype 2/3 infection? J Hepatol 2011;54:835–6. Author reply 6–7.
   PubMed Web of Science ®Google Scholar
• Lagging M, Duberg AS, Wejstal R, Weiland O, Lindh M, Aleman S, et al. Treatment of hepatitis C virus infection in adults and children: updated Swedish consensus recommendations. Scand J Infect Dis 2012;44:502–21.
   PubMed Web of Science ®Google Scholar
• Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, Shianna KV, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010;464:405–8.
   PubMed Web of Science ®Google Scholar
• Lagging M, Rembeck K, Waldenstrom J, Nilsson S, Nystrom K, Martner A, et al. ITPA variants are associated with reduced relapse rate but not with early virological responses following HCV genotype 2/3 therapy. Hepatology 2130;60:502–1.
   Google Scholar
• Rembeck K, Waldenstrom J, Hellstrand K, Nilsson S, Nystrom K, Martner A, et al. Variants of the ITPase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3. Hepatology 2014;59:2131–9.
   PubMed Web of Science ®Google Scholar
• Clark PJ, Aghemo A, Degasperi E, Galmozzi E, Urban TJ, Vock DM, et al. Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy. J Viral Hepat 2013;20:858–66.
   PubMed Web of Science ®Google Scholar
• Sumi S, Marinaki AM, Arenas M, Fairbanks L, Shobowale-Bakre M, Rees DC, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Human Genet 2002;111:360–7.
   PubMed Web of Science ®Google Scholar
• Shipkova M, Lorenz K, Oellerich M, Wieland E, von Ahsen N. Measurement of erythrocyte inosine triphosphate pyrophosphohydrolase (ITPA) activity by HPLC and correlation of ITPA genotype-phenotype in a Caucasian population. Clin Chem 2006;52:240–7.
   PubMed Web of Science ®Google Scholar
• Maeda T, Sumi S, Ueta A, Ohkubo Y, Ito T, Marinaki AM, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency in the Japanese population. Mol Genet Metab 2005;85:271–9.
   PubMed Web of Science ®Google Scholar
• Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696–9.
   PubMed Web of Science ®Google Scholar
• Westin J, Nordlinder H, Lagging M, Norkrans G, Wejstal R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 2002;37:837–42.
   PubMed Web of Science ®Google Scholar
• Leutscher PD, Lagging M, Buhl MR, Pedersen C, Norkrans G, Langeland N, et al. Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. Hepatology 2010;52:430–5.
   PubMed Web of Science ®Google Scholar